Cleerly ISCHEMIA vs Zio ECG Utilization Software (ZEUS) System

Tool B (ZEUS) offers a more comprehensive usability experience, featuring a ZioSuite web portal and mobile application for healthcare professionals, alongside a patient-centric wearable design (Zio monitor) and a dedicated MyZio patient app for symptom logging and education. The Zio monitor has received a Good Design Award for its ergonomic and discreet design, enhancing patient comfort and compliance. While Tool A (Cleerly ISCHEMIA) provides an interactive web-based platform and concise reports, it lacks the explicit mobile application for clinicians and the patient-focused wearable design that Tool B offers.

Both tools demonstrate significant clinical value, backed by FDA clearance and robust clinical validation in their respective specialties. Tool A (Cleerly ISCHEMIA) provides a novel, non-invasive 3-in-1 assessment of atherosclerosis, stenosis, and ischemia from CCTA, with high diagnostic accuracy and prognostic utility for major adverse cardiovascular events (MACE). Tool B (ZEUS) offers superior arrhythmia detection through continuous ECG monitoring and deep-learned AI algorithms, performing at the level of cardiologists and leading to higher diagnostic yield and reduced retesting compared to traditional methods. Their distinct contributions to cardiac care are equally impactful.

While both tools require direct contact for specific pricing, Tool B (ZEUS) offers greater transparency regarding reimbursement and patient costs. The Zio system is covered by Medicare nationwide and by major commercial insurance plans, with proposed Medicare rates for its associated monitoring service publicly available. iRhythm also provides patient financial assistance programs. Tool A (Cleerly ISCHEMIA) states pricing varies by provider and mentions CPT codes, but offers less public detail on insurance coverage or patient financial support.

Tool B (ZEUS) exhibits stronger enterprise readiness, particularly through its established HL7-based EHR integration and a strategic partnership with Epic via the Aura network. This collaboration is estimated to save health systems significant integration time and has facilitated over 1.5 million registrations through EHR-integrated customers. Tool A (Cleerly ISCHEMIA) offers API integration with PowerScribe and uses a VPN or virtual appliance for data transfer, which are standard, but Tool B's deep, proven EHR integration with a major vendor like Epic gives it a distinct advantage for large-scale deployments.

Both tools represent significant innovation in their respective domains. Cleerly ISCHEMIA (Tool A) is innovative for its AI-enabled non-invasive fractional flow reserve (FFR) estimation and comprehensive 3-in-1 assessment of atherosclerosis, stenosis, and ischemia from a single CCTA scan. ZEUS (Tool B) is innovative for its deep-learned AI algorithms that analyze continuous ECG data from wearable biosensors for up to 14 days, providing diagnostic accuracy comparable to cardiologists and being recognized for its groundbreaking impact in wearable medical technology. Both are pushing the boundaries of AI in cardiology in distinct and impactful ways.

Tool B (ZEUS) provides more comprehensive and publicly accessible support and documentation resources. iRhythm offers a 'Clinical Resource Center,' detailed 'Instructions for Use' for its devices and software, and readily available Customer Care contact information for both patients and clinicians, including FAQs and troubleshooting guides. Tool A (Cleerly ISCHEMIA) lacks specific public details regarding its support and documentation offerings, with general information limited to requesting a demo.